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Introduction
Neuroblastoma is a neural crest–derived malignancy that accounts 
for approximately 15% of pediatric cancer death (1). Based on bio-
logical and clinical features such as age at diagnosis, stage of disease 
(L1, L2, M, and Ms), and molecular markers such as MYCN onco-
gene amplification, patients are divided into low-, intermediate-, 
and high-risk groups (2). Despite extensive multi-agent therapy, 
a considerable number of high-risk-group patients, determined 
with MYCN amplification and/or metastatic disease stage (stage 
M), have a poor clinical outcome and do not respond to therapy or 
relapse after treatment (1). Therefore, there is an urgent need to 
identify novel drugs or treatment strategies for these patients.
Cancer cells often acquire genetic mutations and abnormal gene 
expression in extrinsic and intrinsic apoptotic pathways (3). There-
fore, alternative caspase-independent cell death modalities such 
as necroptosis (4, 5) and ferroptosis (6) could provide alternative 
treatment paradigms to eradicate apoptosis-resistant cancer cells 
(7). Necroptosis, the best-characterized form of regulated necrosis, 
is mediated by the concerted action of receptor-interacting protein 
kinase 3 (RIPK3) and mixed-lineage kinase domain–like (MLKL) 
(8). Ferroptosis is triggered by inactivation of the lipid repair enzyme 
glutathione peroxidase 4 (GPX4), which is followed by accumulation 
of toxic lipid peroxides leading to cell death (6, 9). The redox-active 
iron contributes to the execution of ferroptosis by promoting forma-
tion of phospholipid peroxyl radicals (10), which characterizes ferro-
ptosis as an iron-catalyzed form of necrosis. Because neoplastic cells 
have higher levels of iron than nonmalignant cells (11), exploiting 
ferroptosis has proven an alternative and highly efficient way to kill 
therapy-resistant cancer cells (12).
Using a natural anticancer agent, withaferin A (WA), we now 
demonstrate that ferroptosis is a potent anticancer strategy to treat 
high-risk neuroblastoma. We further show that WA-induced fer-
roptosis in neuroblastoma involves a double-edged mechanism. 
On the one hand, WA drops the protein level and activity of GPX4, 
which resembles the canonical ferroptosis-inducing pathway. 
On the other hand, WA induces a novel noncanonical ferroptosis 
pathway by increasing the labile Fe(II) pool upon excessive acti-
vation of heme oxygenase 1 (HMOX1) through direct targeting of 
Kelch-like ECH-associated protein 1 (KEAP1), which is sufficient 
to induce lipid peroxidation. This double-edged targeting mech-
anism results in high efficacy of WA compared with etoposide 
and cisplatin in killing a heterogeneous panel of high-risk neu-
roblastoma cells, and in suppressing neuroblastoma xenograft 
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glutamate antiporter (6). Interestingly, cell death induced by WA 
was blocked by this panel of ferroptosis inhibitors in both IMR-32 
and SK-N-SH cells (Figure 1C, Supplemental Figure 1H, and Supple-
mental Table 3). Note that the class II FINs (1S,3R)-RSL3 (RSL3) and 
ML162 also effectively induced ferroptosis in a panel of high-risk 
neuroblastoma cell lines, while the class I FIN erastin was less effec-
tive in some cell lines (Supplemental Figure 1, H and I).
Considering that oxidative stress drives lipid peroxidation in 
ferroptosis, we analyzed both parameters after a WA challenge 
using the fluorochromes DHR123 and C11-BODIPY, respectively. 
We found that WA induces an oxidative burst (Supplemental 
Figure 1J) and an increase in lipid peroxidation in IMR-32 neuro-
blastoma cells (Figure 1D), which further supported a ferroptotic 
phenotype. Iron chelation using deferoxamine (DFO) blocked 
lipid peroxidation (Figure 1D), highlighting the catalytic role of 
iron in ferroptosis. Ferrostatin-1 (Fer1) was less effective than 
DFO in blocking WA-induced lipid peroxidation (Figure 1D) 
compared with erastin-induced lipid peroxidation (Supplemen-
tal Figure 1K). Lowering the dose of WA or increasing the dose 
of Fer1 did not further reduce lipid ROS to baseline (Supple-
mental Figure 1L). We observed the same incomplete protection 
against lipid hydroperoxide generation by Fer1 treatment using 
the class II FIN RSL3 (Supplemental Figure 1M). Lipid peroxida-
tion could not be detected using a nonferroptotic trigger such as 
staurosporine (Supplemental Figure 1N). Conclusively we show 
that WA induces a necrotic-like cell death that presents all the 
hallmarks of ferroptosis.
WA acts as a natural class II ferroptosis-inducing agent in neu-
roblastoma. GPX4 inactivation is one of the key features of ferro-
ptosis, which occurs either through a drop in glutathione (GSH) 
levels or by direct targeting of GPX4 (6). In contrast to the class 
I FIN erastin, we did not observe a significant drop in GSH levels 
in the neuroblastoma cells following WA treatment (Supplemental 
Figure 1O). This observation could indicate that the ferroptosis- 
inducing action of WA may be attributed to binding and inactiva-
tion of GPX4, as previously shown for the class II FIN RSL3 (6). 
In line with our reasoning, we found a drop in the GPX4 protein 
level at both a cytotoxic high and medium dose of WA (Figure 
1E), resulting in a loss of GPX4 activity (Supplemental Figure 1P). 
Pull-down of WA from lysates of cells treated with biotinylated 
WA revealed GPX4 binding in the presence of a high dose of WA, 
but not in response to a cytotoxic medium dose of WA (Figure 1F). 
Accordingly, overexpression of WT GPX4 in IMR-32 cells delayed 
ferroptosis in response to a medium dose of WA, while no inhibi-
tion was observed in response to a high dose of WA (Supplemental 
Figure 1Q). Note that an inactivating mutation of the active site 
selenocysteine of GPX4U46S abrogated the protective effect upon 
overexpression, which underscores the importance of its enzy-
matic activity to protect membranes against ferroptosis induced 
by a medium dose of WA.
WA preferentially alkylates nucleophilic sites such as pro-
tein thiols via Michael addition (21). To verify this mechanism of 
inactivation, we reconstituted WT GPX4 or a mutant in which 
all cysteines, except for the selenocysteine within its catalytic 
center, were mutated to serine (GPX4AllCys/Ser) in tamoxifen- 
induced GPX4-deficient cells (22). While loss of GPX4 in re-
sponse to a high dose of WA was evident in WT GPX4 and 
growth and relapse. To increase the targeting of WA to the tumor, 
we generated WA-encapsulated nanoparticles. This nanome-
dicinal approach allowed systemic application and the effective 
suppression of tumor growth. Conclusively, the discovery of WA- 
mediated ferroptosis by targeting of GPX4 and/or enhancing of the 
labile Fe(II) pool through excessive HMOX1 activation might open 
new perspectives for the development of novel treatments in cell 
death–resistant cancer cells.
Results
WA kills etoposide-resistant neuroblastoma cells by inducing lipid 
peroxidation. Therapy resistance is a major issue in more than half 
of high-risk neuroblastoma patients. We and others have reported 
on the profound anticancer effect of WA (Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI99032DS1) especially on therapy-resistant 
cancer cells (13, 14). Therefore, we examined the sensitivity of 
a panel of high-risk neuroblastoma cell lines to WA, including 
MYCN-amplified and nonamplified cells. We observed that WA 
is significantly more potent than the standard chemotherapeutics 
etoposide and cisplatin in killing these different neuroblastoma 
cell lines (Figure 1A and Supplemental Table 1).
We used 2 different neuroblastoma cell lines, one with MYCN 
amplification (IMR-32 cells) and one without (SK-N-SH cells), to 
further study the dose-response effects and mechanism of action of 
WA. The optimal cytotoxic dose was determined for both cell lines 
(Supplemental Figure 1, B and C). Notably, a structurally related 
inactive withanolide with a different epoxy stereo-orientation, 
withanone (WN), was not toxic to neuroblastoma cells (Supplemen-
tal Figure 1B), which is similar to what was previously observed in 
endothelial cells (15, 16). Although previous studies in a variety of 
cancer cell lines indicated WA-induced apoptosis (17), we observed 
that treatment with the caspase inhibitor Z-VAD-FMK did not block 
WA-induced cell death in IMR-32 or SK-N-SH cells (Supplemental 
Figure 1D). Time course analysis revealed no caspase activity or 
proteolytic processing of caspases during WA-induced cell death, 
while robust caspase activity was observed upon staurosporine 
treatment (Supplemental Figure 1, E and F). Live cell imaging 
revealed that WA-induced cell death occurred with a necrotic mor-
phology including cell rounding, swelling, and plasma membrane 
rupture (Figure 1B). Lysosomal membrane permeabilization also 
occurred before plasma membrane rupture during cellular disin-
tegration (Supplemental Videos 1 and 2), similar to what we have 
observed for other types of necrosis (18).
Since WA triggered caspase-independent cell death with 
necrotic morphology, we next investigated whether necroptosis, as a 
prototype form of regulated necrosis, was involved (7). Before expo-
sure to WA, we pretreated the neuroblastoma cells with a panel of 
necroptosis inhibitors. With the exceptions of necrostatin-1 (Nec1) 
and butylated hydroxyanisole (BHA), none of the necroptosis inhib-
itors blocked WA-induced cell death in IMR-32 cells nor SK-N-SH 
cells (Supplemental Figure 1G and Supplemental Table 2). Nec1 and 
the lipophilic antioxidant BHA were previously shown to also inhibit 
ferroptosis (19, 20), although the precise mechanism in case of Nec1 
remains elusive. Next, we pretreated the IMR-32 cells with a panel 
of ferroptosis inhibitors before exposing the cells to WA or erastin, a 
class I ferroptosis-inducing compound (FIN) that blocks the cystine/
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suggests that a high dose of WA interacts preferentially with 
cysteines, instead of selenocysteine. 
Since DTT is a cysteine-rich thiol donor, we next evaluated 
whether cotreatment with DTT could compete for cysteine- 
GPX4U46C reconstituted cells, no drop was observed in the 
GPX4AllCys/Ser mutant (Figure 1G and Supplemental Figure 1R). 
Note that the structurally related inactive withanolide WN did 
not change GPX4 protein levels (Supplemental Figure 1R). This 
Figure 1. WA acts as a class II ferroptosis-inducing agent to kill etoposide- and cisplatin-resistant neuroblastoma cells. (A) Heatmap representing cell death 
sensitivity of various high-risk neuroblastoma cell lines after exposure to WA, etoposide (Eto), and cisplatin (Cis). See also Supplemental Table 1. SG, Sytox 
Green. (B) Snapshots from a live cell imaging of IMR-32 and SK-N-SH cells treated with WA. See also Supplemental Videos 1 and 2. Green fluorescent staining 
represents SytoxGreen. (C) Heatmap representing the cell death sensitivity of IMR-32 and SK-N-SH cells after exposure to 1 μM or 10 μM WA, respectively, in the 
absence or presence of different ferroptosis inhibitors, including the iron chelator ciclopirox olamine (CPX, 5 M), the lipid peroxidation inhibitor ferrostatin-1 (Fer1, 
500 nM), the lipophilic antioxidant α-tocopherol (αToco, 100 μM), and the kinase inhibitors U0126 (10 μM) and Flt3 inhibitor (500nM). See also Supplemental 
Table 3. (D) Flow cytometric analysis of the lipid peroxidation sensor (C11-BODIPY-581/591 dye) on live-gated cells (SytoxBlue-negative cells) after treatment of 
IMR-32 cells with WA. (E) Western blot analysis revealing GPX4 and β-tubulin expression in IMR-32 cells treated with a high dose (10 μM) and a medium dose 
(1 μM) of WA. (F) Western blot analysis revealing GPX4 and actin after immunoprecipitation of biotin-WA in lysates of IMR-32 cells treated with a high dose (10 
μM) and a medium dose (1 μM) of biotin-WA. (G) Western blot analysis revealing GPX4 expression in GPX4-depleted mouse embryonic fibroblasts (MEFs) recon-
stituted with GPX4 or GPX4AllCys/Ser 5 hours after treatment with WA (10 μM). (H) Molecular modeling simulation of WA docked on Cys107 of human GPX4 crystal 
structure (2OBI). See also Supplemental Table 4 and Supplemental Video 3. **P < 0.01, ****P < 0.0001, 2-way ANOVA test (A).
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to medium dose of WA, while this was not the case in response to 
a noncytotoxic low dose or a cytotoxic high dose of WA. HMOX1 
expression is controlled by the NRF2/antioxidant response ele-
ment signaling pathway (23). The NRF2 transcription factor is 
kept in check by Kelch-like ECH-associated protein 1–dependent 
(KEAP1-dependent) degradative ubiquitination (23). In line with 
this, we observed decreased levels of KEAP1 along with increased 
levels of NRF2 in conditions in which HMOX1 is upregulated (Fig-
ure 2D). Pull-down of WA from lysates of cells treated with bioti-
nylated WA revealed KEAP1 binding in the presence of a medium 
dose of WA (Figure 2E). Thus, while a medium dose of WA did not 
bind to GPX4, it bound KEAP1, resulting in strong upregulation 
of HMOX1. We found that pharmacological inhibition of HMOX1 
activity strongly inhibited ferroptotic cell death after exposure 
to a medium dose of WA, while a transient delay was observed 
upon exposure to a high dose (Figure 2F). Similarly, RNAi- 
mediated knockdown of HMOX1 suppressed ferroptosis in 
response to a medium dose of WA, while no protection was 
observed upon exposure to a high dose of WA (Figure 2, G and 
H). Both findings indicate a cytotoxic instead of protective role 
of HMOX1 in ferroptosis induced by a medium dose of WA. This 
seems counterintuitive because HMOX1 activity is part of an anti-
oxidant and detoxifying system.
HMOX1 detoxifies heme into biliverdin, releasing carbon 
monoxide and Fe(II) (24). Addition of the HMOX1 substrate hemin 
sensitized cells to WA-induced ferroptosis in response to a medium 
dose, but not a high dose (Figure 2I). Like cells treated with a 
medium dose of WA, we found that administration of hemin 
induces a strong upregulation of HMOX1 (Figure 2J) and its 
dose-dependent cytotoxicity is blocked by an HMOX1 inhibitor 
(ZnPP) or a panel of ferroptosis inhibitors (Figure 2K). Essential-
ly, the detoxification of heme by HMOX1 results in the release 
of labile Fe(II) (24), which has been proposed to be involved in 
oxidative stress–mediated cell death (25). In line with our hypoth-
esis, we revealed a time-dependent increase in labile Fe(II) in 
response to WA using an Fe(II)-selective probe, RhoNox-1 (26) (Fig-
ure 2L). Adding hemin to IMR-32 cells also increased WA-induced 
elevation of the labile Fe(II) pool (Figure 2M). In addition, increas-
ing the Fe(II) pool in the cell (Supplemental Figure 2C) using fer-
rous ammonium sulfate [(NH4)2Fe(SO4)2] induced cell death that 
could be blocked by ferroptosis inhibitors (Figure 2N), suggesting 
that increasing the labile Fe(II) pool as such is sufficient to initiate 
ferroptosis in neuroblastoma cells. Note that, consistent with the 
observed upregulation of FTH1 in our transcriptome analysis (Fig-
ure 2B and Supplemental Figure 2B), we also observed a stronger 
upregulation of FTH1 in response to a medium dose of WA, com-
pared with a high dose (Supplemental Figure 2D). This response 
may indicate an attempt to buffer the increase in Fe(II) that fol-
lowed WA-induced excessive activation of HMOX1. In summary, 
ferroptosis induced by a medium dose of WA is dependent on 
an increase in the labile Fe(II) pool upon excessive activation of 
HMOX1. Moreover, hemin- or (NH4)2Fe(SO4)2-induced increase in 
labile Fe(II) is sufficient to induce ferroptosis.
WA eradicates high-risk neuroblastoma tumors and shows lower 
relapse rates compared with etoposide. Because WA was effective 
in killing a panel of high-risk neuroblastoma cells in vitro, we 
next sought to investigate the potency of WA to suppress tumor 
dependent WA binding to GPX4. As expected, upon addition of 
excess amounts of DTT to compete for GPX4 binding, interaction 
between biotinylated WA and GPX4 was completely lost, further 
supporting the alkylation of GPX4 by WA (Supplemental Figure 1S). 
To support our finding that WA covalently binds to GPX4 through 
cysteines, we performed molecular modeling to investigate the 
propensity of WA to bind solvent-exposed cysteines of human 
GPX4 (Protein Data Bank ID 2OBI). In silico modeling showed 
overall lower binding energy values of WA for cysteines compared 
with the previously identified GPX4-targeting agents altretamine 
and ML162 (Supplemental Table 4). The conserved Cys107 is 
predicted to be the most favorable site for WA-mediated alkyla-
tion (Figure 1H and Supplemental Video 3). Taken together, these 
data suggest a dual action mechanism of WA-induced ferroptosis. 
At high dose, WA acts as a class II (GPX4-targeting) ferroptosis 
inducer, while at cytotoxic medium dose, ferroptosis is induced 
through an alternative mechanism.
HMOX1-mediated increase in the labile Fe(II) pool boosts ferro-
ptosis. To explore the mechanism of action of ferroptosis induction 
in response to a medium dose of WA, we performed a genome-
wide transcriptome analysis in IMR-32 and SK-N-SH cells. Inter-
estingly, we identified heme oxygenase-1 (HMOX1) as the top 
upregulated gene by WA in both IMR-32 and SK-N-SH neuro-
blastoma cells. Ingenuity Pathway Analysis (IPA) of the data 
set indicated nuclear factor–like 2–mediated (NRF2-mediated) 
oxidative stress as one of the top signaling pathways induced 
by WA, but not WN, in IMR-32 cells (Figure 2, A and B) and SK- 
N-SH cells (Supplemental Figure 2, A and B). This observation 
of a similar transcriptome profile in both subtypes is remarkable, 
given that there can be large disparities in the way that neuroblas-
toma subtypes respond to drug treatments. Validation of WA- 
mediated regulation of HMOX1 confirmed its upregulation at the 
mRNA (Figure 2C) and the protein level (Figure 2D) in response 
Figure 2. WA increases intracellular labile Fe(II) upon excessive activa-
tion of HMOX1, which is sufficient to induce ferroptosis. (A) IPA of genes 
differentially expressed after treatment with WA (1μM) in IMR-32 cells. 
(B) Gene expression profiles of Ctrl, WA-treated, and WN-treated IMR-32 
cells. Color key legend represents Z score values. (C) Relative HMOX1 
mRNA expression in IMR-32 cells after WA-treatment. (D) Western blot 
revealing KEAP1, NRF2, and HMOX1 in IMR-32 cells treated with WA. (E) 
Western blot revealing KEAP1 after immunoprecipitation of biotin-WA 
in lysates of IMR-32 cells treated with biotin-WA (1 μM). (F) Percentage 
of cell death induced by WA in the presence/absence of HMOX1 inhibitor 
(ZnPP). (G) Western blot revealing HMOX1 in response to WA (1 μM). (H) 
Percentage of cell death induced by WA upon RNAi-mediated knockdown 
of HMOX1. The results are representative of 2 independent experiments. 
(I) Percentage of cell death induced by WA in the presence/absence of 
hemin. (J) Western blot revealing HMOX1 in response to hemin (10 μM). (K) 
Heatmap representing the sensitivity of IMR-32 cells in response to hemin 
in the presence of ferroptosis inhibitors. See also Supplemental Table 5. 
(L) Cellular levels of labile Fe(II), using RhoNox-1, in function of time in 
response to WA (1 μM). (M) Cellular levels of labile Fe(II), using RhoNox-1, 8 
hours after treatment with WA (1 μM), hemin (10 μM), or the combination. 
MFI, mean fluorescence intensity. (N) Heatmap representing cell death 
sensitivity of IMR-32 cells in response to (NH4)2Fe(SO4)2 in the absence/
presence of ferroptosis inhibitors. See also Supplemental Table 6. The 
combined results of 2 or 3 independent experiments are shown for F, I, K, 
and N. Error bars represent SEM. *P < 0.05, ***P < 0.001, ****P < 0.0001, 
2-way ANOVA test (F, I, L,and M). NDGA, nordihydroguaiaretic acid.
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Figure 3. WA-eradicated high-
risk neuroblastoma tumors show 
decreased GPX4 expression, 
increased HMOX1 expression, and 
decreased relapse rates. (A and B) 
Light microscopic pictures of H&E 
staining of tumor sections (A) and 
quantification of tumor size area 
(B) representing effect of WA and 
vehicle (Ctrl) on SH-EP–derived 
tumors in a chicken chorioallan-
toic membrane (CAM) model. The 
combined results of 2 independent 
experiments are shown. Error bars 
represent SEM; n = 10 (Ctrl), n = 10 
(WA). (C) Quantification of tumor 
growth rates after therapeutic 
treatment regime (100–200 mm3 at 
the start of treatment) with vehicle 
(Ctrl), WA, or etoposide (Eto). The 
results of 1 experiment for etoposide 
and combined results of 2 indepen-
dent experiments for WA are shown. 
Each point indicates an individual 
mouse. Error bars represent SEM;  
n = 11 (Ctrl), n = 13 (WA), n = 6 (Eto). 
(D) Quantification of tumor growth 
rates in mice after termination of 
treatment with WA and Eto (tumor 
size cutoff below 180 mm3 at time 
of termination of the treatment). 
(E–I) Immunohistochemical staining 
revealing proliferation using Ki67 
antibody (E), DNA fragmentation 
using TUNEL staining (F), caspase-3 
activation using anti–active 
caspase-3 antibodies (G), GPX4 (H), 
and HMOX1 expression level (I) in 
tumor sections after therapeutic 
treatment regime with vehicle (Ctrl) 
or WA. (J) Western blot revealing 
GPX4 and HMOX1 in lysates of 
tumor sections after therapeutic 
treatment regime with vehicle (Ctrl) 
or WA. ****P < 0.0001, 2-tailed  
t test (B), 1-way ANOVA (C).
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growth. Before exploring xenograft in vivo models, we investi-
gated the effect of WA on an ex vivo tumor growth model using 
a chicken chorioallantoic membrane assay. These tumors were 
treated for 3 consecutive days with WA or vehicle (Ctrl). Analy-
sis of the histological sections demonstrated eradication of the 
tumor after WA treatment (Figure 3A). Quantification of the 
tumor size revealed a significant reduction after WA inoculation 
(Figure 3B). Next, to test the chemopreventive potential of WA 
in an experimental neuroblastoma xenograft mouse model, we 
subjected subcutaneously growing IMR-32 cells to WA or vehicle 
(Ctrl) starting 1 day after implantation. Daily monitoring of the 
tumor size demonstrated a significant decrease in tumor growth 
rate after WA treatment regime (Supplemental Figure 3, A and 
B). To validate the chemotherapeutic potential of WA, we first 
started the intratumoral WA treatment when the tumor reached 
a volume of approximately 60 mm3. This approach resulted in a 
significant retardation in tumor growth (Supplemental Figure 3, 
C and D). Next, we compared the efficacy of intratumoral WA 
treatment with etoposide in vascularized neuroblastoma tumors 
of approximately 100–200 mm3. WA was as effective as the 
standard chemotherapeutic etoposide in suppressing the tumor 
growth rate (Figure 3C and Supplemental Figure 3E). Upon ter-
mination of the treatment, we noted that 4 out of 5 mice did not 
show any relapse, while all mice treated with etoposide showed 
a relapse within 10–15 days (Figure 3D and Supplemental Fig-
ure 3F). This could be of utmost importance considering that 
as many as 50%–60% of children with high-risk neuroblastoma 
will eventually die upon relapse.
Tumor regression occurs through lipid peroxidation–mediated 
cell death. Analysis of the tumor samples allowed us to verify 
whether the mode of action of the cytotoxicity of WA was simi-
lar in vivo compared with our experiments performed in neuro-
blastoma cells. Immunohistochemical staining of tumor sections 
with a marker for proliferation (anti-Ki67) showed a nearly absent 
staining in WA-treated tumors compared with tumors treated with 
vehicle (Ctrl) (Figure 3E). In addition to tumor growth inhibition, 
we observed that WA induced massive cell death reflected by 
TUNEL positivity (Figure 3F) without caspase-3 activation (Figure 
3G). The cell death induced by WA in the tumor is associated with 
an infiltration of large numbers of CD45-positive immune cells 
(Supplemental Figure 3G). Moreover, in accordance with our pro-
posed mechanism of action, WA-treated tumors showed a drop in 
GPX4 expression (Figure 3, H and J) and a concomitant increase 
in HMOX1 expression levels (Figure 3, I and J). Because lipid per-
oxidation is a key feature in ferroptosis, we finally performed liq-
uid chromatography–mass spectrometry–based redox-lipidomics 
analysis (27) of tumors treated with WA or vehicle (Ctrl) (Figure 
4 and Supplemental Figure 4). This analysis revealed an accumu-
lation of peroxidized lipid species in WA-treated tumors reflected 
by a significant increase in the contents of oxygenated polyun-
saturated species in several classes of phospholipids. This effect 
was particularly robust in phosphatidylglycerol (PG) and phos-
phatidylinositol (PI) but also observable in other major classes of 
phospholipids, such as phosphatidylcholine (PC), phosphatidy-
lethanolamine (PE), and phosphatidylserine (PS), with the notable 
exception of cardiolipin (CL). The elevated levels of oxygenated 
(ox) species of PG and PI contained hydroperoxy- (+2O) or dihy-
droperoxy- (+4O) groups, which is likely due to the insufficiency 
of GPX4-driven mechanism of reduction of phospholipid hydrop-
eroxides to respective hydroxy-derivatives (Figure 4A). Oxidation 
products in other classes of phospholipids were represented by 
mono-oxygenated species (Figure 4B), likely hydroxy-derivatives 
that are usually formed as products of GPX4-dependent reduc-
tive metabolism. In addition, significant elevation of the contents 
of several types of lysophospholipids was found in WA-treated 
tumors. The high levels of lysophospholipids were detected in 
PC, PE, PS, and CL as LPC, LPE, LPS, and monolyso-cardiolipin 
(MLCL), respectively (Figure 4C). It is interesting that no elevated 
levels of lysophospholipids were found for PG and PI, whose 
oxidation yielded hydroperoxy-derivatives (Figure 4A). Despite 
the accumulation of MLCL in WA-treated tumors, we did not 
observe an accumulation of any oxygenated CL species (Sup-
plemental Figure 4). Given that mono-oxygenated CL species 
are highly specific for the execution of intrinsic apoptotic pro-
gram (28), these data corroborate that WA induced a caspase- 
independent form of cell death in neuroblastoma tumors with 
clear features of lipid peroxidation compatible with the induction 
of ferroptosis. Together, these data indicate the potential of WA 
to induce massive cell death in neuroblastoma tumors with clear 
features of ferroptosis, which subsequently triggers the infiltration 
of high numbers of immune cells.
Nano-targeting of WA avoids systemic side effects and suppresses 
tumor growth. Because of poor solubility of WA in water and severe 
weight loss–related adverse effects upon systemic injection (Fig-
ure 5D), we formulated WA in a novel amphiphilic degradable pH- 
sensitive nanocarrier to allow systemic administration in a neuro-
blastoma xenograft model (Figure 5A). In vitro characterization of 
the WA nanoparticles (WA-NPs) revealed a size of approximately 
10–50 nm (Figure 5B) and an equal cytotoxic efficacy in IMR-32 
cells compared with nonencapsulated WA (Figure 5C). Note that we 
tested 2 other formulation approaches, which were unsuccessful. 
Using a different polymeric excipient for physical encapsula-
tion requiring tetrahydrofuran for cosolubilization of polymer 
and drug, followed by solvent displacement in aqueous medium 
(29), we observed cytotoxicity of the empty vehicle (Empty-NP2) 
(Supplemental Figure 5A). Commonly used polymer amphiphilic 
excipients for drug encapsulation such as those based on poly 
(ethyleneglycol-block-lactic acid) and poly(ethyleneglycol-block- 
[glycolic-co-lactic acid]) were not capable of stably accommodating 
WA because of precipitation of WA crystals in aqueous medium. 
Using a WA-polymer conjugation approach by covalent linking of a 
hydrophilic polymer [poly(N,N-dimethylacrylamide)] to a hydroxyl 
moiety of WA via an ester bond (30), we observed minor cytotoxic 
activity of WA-NP3 in IMR-32 neuroblastoma cells (Supplemental 
Figure 5A), and no tumor regressing activity in vivo (Supplemental 
Figure 5B). To confirm enhanced targeting to the tumor site due to 
enhanced permeability and retention (EPR) effect (31), nanopar-
ticles fluorescently labeled with Cy5 (Cy5-NPs) were injected 
intraperitoneally (Figure 5E). Systemic application of WA-NPs to 
mice bearing tumors with a volume of approximately 60–70 mm3 
significantly suppressed the growth of neuroblastoma tumors (Figure 
5F) without significant weight loss (Figure 5G). In conclusion, WA 
seems to be a promising candidate for further therapeutic exploita-
tion using novel targeting strategies such as cancer nanomedicine.
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branes against lipid peroxidation, and its targeted degradation 
typically results in ferroptosis (32). On the other hand, a medium 
dose of WA induced a massive upregulation of HMOX1, which 
was followed by an increase in cellular labile Fe(II), and conse-
quent ferroptosis. The mechanism by which WA upregulates 
HMOX1 occurs via targeting of KEAP1, the negative regulator of 
NRF2, as we recently reported for endothelial cells (15). Pharma-
cological inhibition or knockdown of HMOX1 blocked ferroptosis 
Discussion
In the present study, the natural phytochemical WA isolated 
from Withania somnifera roots (17) was identified as a novel nat-
ural compound that kills a panel of high-risk neuroblastoma cells 
(mostly quite etoposide and cisplatin resistant) through a novel 
double-edged ferroptosis-inducing mechanism (Figure 5H). On 
one hand, WA acts as a class II FIN (6), which resulted in a rapid 
drop in expression and activity of GPX4. GPX4 protects mem-
Figure 4. Oxidative lipidomics profiles show massive lipid peroxidation in neuroblastoma tumors treated with WA. (A and B) Levels of oxygenated 
phospholipid species, with significantly higher levels (33 species) detected in neuroblastoma tumors from mice treated with WA compared with vehicle- 
treated mice (Ctrl). Error bars represent SEM; n = 3. (C) Levels of lysophospholipids, with significant increase (22 species) in neuroblastoma tumors treated 
with WA. Error bars represent SEM; n = 3. PL, phospholipids; PG, phosphatidylglycerol; PI, phosphatidylinositol; PC, phosphatidylcholine; PE, phosphatidy-
lethanolamine; PS, phosphatidylserine; L, lyso; MLCL, monolyso-cardiolipin. *P < 0.05, 2-tailed t test (A–C).
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Additional research is needed to verify whether this noncanoni-
cal ferroptosis induction by excessive activation of HMOX1 and 
increase in cellular labile Fe(II) could create new opportunities to 
effectively kill other types of tumor cells.
Neuroblastoma patients have increased levels of iron and 
HMOX1 expression in the tumor tissue and increased ferritin 
levels in plasma (37, 38). Therefore, iron chelation strategies (11, 
39) or HMOX1 inhibition are currently explored to reduce tumor 
growth (38). Our data, however, propose an opposite strategy. In 
the present study, we show that both high levels of labile Fe(II) and 
excessive activation of HMOX1 are important to eradicate neuro-
blastoma through ferroptotic action mechanisms. Therefore, the 
high level of iron, GPX4, and HMOX1 expression in cancer cells 
can be an Achilles’ heel, as it makes tumor cells vulnerable to 
ferroptosis induction upon therapeutic targeting (11, 40).
It is remarkable that the level of protection by Fer1 against 
hydroperoxide formation and ferroptosis in response to RSL3 and a 
high dose of WA (class II FINs) was incomplete compared with the 
induced by a medium dose of WA, which indicates that elevated 
HMOX1 expression and activity have a direct role in ferroptotic 
cell death induced by WA.
Recently, 2 studies reported opposite roles for HMOX1 in 
erastin-induced ferroptosis. A protective role was proposed in 
hepatocellular carcinoma (33) and glioblastoma (34), while a cyto-
toxic role was observed in fibrosarcoma cells (35). We propose 
that the level of HMOX1 upregulation might determine whether 
HMOX1 promotes or inhibits ferroptosis. This biological phenom-
enon resembles hormesis: a moderate level of HMOX1 is cyto-
protective, while excessive HMOX1 activation becomes cytotoxic 
because of an increase in labile Fe(II) due to insufficient buffering 
capacity by ferritin (25, 36). This mechanism of action is under-
scored by the observation that the increase in HMOX1 expres-
sion in response to a medium dose of WA was 10-fold higher 
than the increase in FTH1 expression. In addition, we identified 
that increasing the labile Fe(II) pool by adding (NH4)2Fe(SO4)2 or 
hemin is sufficient to trigger ferroptosis in neuroblastoma cells. 
Figure 5. Nano-targeting of WA avoids 
systemic side effects and suppresses tumor 
growth. (A) Schematic representation of 
the amphiphilic degradable pH-sensitive 
nanoparticle encapsulating WA (WA-NP). 
(B) Histogram indicating the size of empty 
(Empty-NP) and WA-encapsulated nanopar-
ticles (WA-NP). d;nm means diameter of 
nanoparticles in nanometer. (C) Percentage 
of cell death in function of time triggered 
by WA-NPs, Empty-NPs, and WA in IMR-32 
cells. (D) Percentage of body weight change 
in mice 4 days after daily i.p. injection of WA 
and vehicle. (E) In vivo fluorescence images 
of neuroblastoma tumor xenografts in nude 
mice injected i.p. with Cy5 and Cy5-loaded 
nanoparticles (Cy5-NPs). (F) Percentage of 
body weight change in mice 9 days after 
daily i.p. injection of empty (Empty-NP) or 
WA-encapsulated nanoparticles (WA-NP). 
(G) Quantification of tumor growth rates 
after therapeutic treatment regime (60–70 
mm3 at the start of injection) with empty 
(Empty-NP) or WA-encapsulated nanopar-
ticles (WA-NP). Each point indicates an 
individual mouse. Error bars represents 
SEM; n = 8 per group. (H) PL•, phospholipid 
radical; PLOO•, phospholipid peroxyradical; 
LOOH, phospholipid hydroperoxide; PLOH, 
phospholipid alcohol. Schematic representa-
tion of a double-edged ferroptosis induction 
mechanism upon WA exposure. WA induces 
uncontrolled lipid peroxidation and ferropto-
sis through inactivation of GPX4 (canonical 
ferroptosis induction) and excessive activa-
tion of HMOX1 followed by an increase in the 
labile Fe(II) pool (noncanonical ferroptosis 
induction). Inhibiting the lipid detoxification 
process, by inactivating GPX4, as well as 
fueling the reactive free radical chain process 
by increasing the labile Fe(II) pool effectively 
boosts ferroptosis. *P < 0.05;  **P < 0.001, 
2-tailed t test (D and G).
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This implies that WA might be a promising candidate for further 
therapeutic exploitation.
In summary, we have shown the high effectiveness of WA in 
eradicating high-risk neuroblastoma due to a double-edged ferro-
ptosis mechanism. A high dose of WA makes tumor cells vulnera-
ble to ferroptosis through GPX4 targeting and inactivation leading 
to canonical ferroptosis induction, while a medium dose of WA 
activates the NRF2 pathway through KEAP1 targeting. This non-
canonical induction of ferroptosis is characterized by an increase 
in intracellular labile Fe(II) upon excessive activation of HMOX1, 
which is sufficient to induce ferroptosis. It will be interesting to 
screen for other compounds that upregulate HMOX1 or the labile 
Fe(II) pool. Additional research to explore how sensitizing thera-
pies (by, e.g., hemin cotreatment), use of more potent WA analogs 
(55), or targeting strategies can further improve the effectiveness 
of WA will expand the therapeutic potential of WA in malignan-
cies such as high-risk neuroblastoma.
Methods
Antibodies and reagents. The following antibodies were used in this study: 
cleaved caspase-3 (Cell Signaling, 9661), β-tubulin (Abcam, ab21058), 
actin (MP Biomedicals, 69100), GPX4 (Abcam, ab41787), CD45 (BD 
Biosciences, 550539), Ki67 (Cell Signaling, 12202S), HMOX1 (Enzo 
Life Sciences, ADI-SPA-896-F), NRF2 (Abcam, ab62352), and KEAP1 
(Proteintech, 10503-2-AP). The following reagents were used: BODIPY 
581/591 C11 probe (Invitrogen, D-3861), DHR123 probe (Thermo Fisher 
Scientific, D23806), SytoxGreen (Thermo Fisher Scientific, S7020), 
streptavidin-Sepharose beads (GE Healthcare, 17-5113-01), diamino-
butyric acid (DAKO, K3468), antigen retrieval solution (DAKO, s2031), 
erastin (Sigma-Aldrich, E-7781; Selleckchem, S7242), withaferin A 
(Altavista Phytochemicals), FeRhoNox-1 (Goryo Chemical, GC901), 
FAS (Sigma-Aldrich, F7002), hemin (Sigma-Aldrich, H9039), ML162 
(Aobious, AOB1514), RSL3 (Selleckchem, S8155), and Matrigel matrix 
(Corning, 356231). DEVD-AMC (Pepta Nova, 3171-V) was used at 20 
μM. Nec1 (Calbiochem, 480065) was used at 10 μM. Fer1 (Xcess Bio-
sciences, 053224) was used at 500 nM. DFO (Sigma-Aldrich, D-9533) 
was used at 100 μM and 1 mM. Necrosulfonamide (NSA; Calbiochem, 
480073) was used at 2.5 μM. BHA (Sigma-Aldrich, B-1253) was used 
at 100 μM. DecylQ (Sigma-Aldrich, D7911) was used at 10 μM. Nor-
dihydroguaiaretic acid (NDGA; Sigma-Aldrich, N-5023) was used 
at 10 μM. α-Tocopherol (Sigma-Aldrich, T3251) was used at 100 μM. 
Ciclopirox olamine (CPX; Sigma-Aldrich, C0415) was used at 5 μM and 
10 μM. FLT3 inhibitor III (Merck, 343022) was used at 500 nM. U0126 
(Sigma-Aldrich, U120) was used at 10 μM. The caspase peptide inhib-
itor Z-VAD-FMK (Bachem, N-1510) was used at 10 μM. The heme 
oxygenase-1 inhibitor (Enzo Life Sciences, ALX-430-049-M025) was 
used at 1.2 μM. Synthesis of biotinylated WA has been described previ-
ously and was provided by P. Vanderveken (15).
Cell lines. IMR-32, SK-N-SH, Kelly, NB69, and CHP-134 cells were 
cultured in RPMI 1640 medium supplemented with 10% FCS and 
l-glutamine (1 mM). NLF cells were cultured in RPMI 1640 medium 
supplemented with 10% FCS, l-glutamine (1 mM), and sodium pyru-
vate (1 mM). SH-EP cells were cultured in DMEM supplemented with 
10% FCS, l-glutamine (1 mM), and sodium pyruvate (1 mM). SH-SY5Y, 
SK-N-AS, SK-N-BE(2)C, and SK-N-DZ cells were cultured in DMEM 
supplemented with 10% FCS and l-glutamine (1 mM). IMR-32 and 
SK-N-SH cells were obtained from Jo Vandesompele, Ghent University 
level of protection in response to erastin (a class I FIN). This might 
be specific to neuroblastoma cells, although a similar incomplete 
protection against hydroperoxides by Fer1 was previously observed 
in Pfa cells upon GPX4 depletion (19) and in hydrogen peroxide– 
treated mouse embryonic fibroblasts (41) and HT1080 cells (9). 
Alternatively, WA might have additional targets that promote 
iron-dependent cell death independent of Fer1-sensitive ferropto-
sis, similar to other covalent modifying agents such as phenethyl 
isothiocyanate (9, 42) and piperlongumine (43). Notably, Fer1 does 
block ferroptosis completely in H2O2-hypersensitive cells in which 
the selenocysteine in GPX4 is mutated to cysteine (41). This indi-
cates that H2O2 induces ferroptosis that is Fer1-inhibitable. How-
ever, in WT cells, you need to overcome GPX4-mediated protection 
against hydroperoxide formation by using a very high concentration 
of H2O2 (millimolar range). Considering the mechanism of action 
of Fer1 as a free radical trap (44), we argue that Fer1 is incapable 
of protecting against excessive levels of lipid ROS induced by, for 
instance, H2O2 or WA, although both induce ferroptosis.
The recent identification of the FDA-approved anticancer 
agents altretamine (45), sorafenib (46), and silica nanoparticles (47) 
as ferroptosis inducers creates high expectations of newly identified 
ferroptosis-inducing agents (32). Our study adds WA as the first 
ferroptosis-inducing natural compound that targets GPX4 (class II 
FIN), which may function as an interesting lead anticancer agent. 
Although limiting cysteine uptake and GSH synthesis has been 
reported as a mechanism to induce ferroptosis, this may be insuffi-
cient to kill certain cancer cells. In several types of cancers, upreg-
ulation of the SLC7A11 protein, a subunit of system XC–, has been 
observed. This overcomes ferroptosis triggered by system XC– inhib-
itors (48, 49). Cysteine can also be supplied via other transporters, 
such as the system ASC transporters (50). In addition, the induc-
tion of GSH depletion in some cancer cells can be compensated by 
other thiol-containing antioxidants such as thioredoxin enzymes 
(51). Therefore, direct targeting and inactivation of GPX4 by class II 
FINs such as WA might circumvent adaptive mechanisms of cancer 
cells that bypass inhibition of system XC– or GSH depletion.
High-risk neuroblastoma patients have poor prognosis and 
show large disparities in drug response due to genetic instability 
and intratumoral heterogeneity (1). We show that WA is equally 
effective in killing neuroblastoma cells with or without MYCN 
amplification, indicating that WA has broad therapeutic potential 
to kill high-risk neuroblastoma independent of its heterogeneity. 
It is remarkable that WA-treated mice that showed a strong regres-
sion of the tumor showed no signs of relapse upon termination of 
the treatment, in contrast to etoposide. This is likely due to the 
resistance of high-risk neuroblastoma cells to etoposide, which 
might allow regrowth of the tumor upon termination of the treat-
ment. Etoposide-induced tumor regression likely acts mainly by 
targeting angiogenesis (52), and WA by targeting both the vascula-
ture (53) and the neuroblastoma tumor.
It is a central theme in cancer therapy that polymeric implants 
(54) or targeted delivery through nanoparticles (40, 47) could 
increase efficacy of cancer treatments and bypass resistance path-
ways. To increase the targeting of WA to the tumor, we generated 
WA-encapsulated nanoparticles using a novel amphiphilic degrad-
able pH-sensitive nanocarrier. This nanomedicine approach 
allowed systemic application and suppressed tumor growth. 
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ly, cells were seeded in a 96-well plate, and all experiments were 
performed in triplicate. The next day cells were preincubated with 
the desired inhibitors for 1 hour or 4 hours (for DFO) then treated 
with stimuli at desired concentrations in the presence of Sytox-
Green (1.7 μM) and DEVD-AMC (20 μM). Afterward, the plate was 
transferred to a temperature- and CO2-controlled FLUOstar Omega 
fluorescence plate reader. The fluorescence intensity of SytoxGreen 
and DEVD-AMC was measured in function of the time at intervals 
of 1 hour with excitation/emission filters of 485/520 nm for Sytox-
Green and 360/460 nm for DEVD-AMC. In each experiment, Triton 
X-100 (0.05%) was used to induce lysis of the cells in at least 3 wells 
of the plate, and its signal intensity was used as 100% cell death ref-
erence. The percentage of the cell death was calculated by the for-
mula (avg. SytoxGreen [stimuli] – avg. SytoxGreen [background]) / 
(avg. SytoxGreen [Triton X-100] – avg. SytoxGreen [background]) 
× 100. Caspase-3 activity was calculated: (avg. DEVD-AMC [stim-
uli] – avg. DEVD-AMC [background]) / (avg. DEVD-AMC [Triton 
X-100] – avg. DEVD-AMC [background]) × 100. The graphs were 
plotted in GraphPad Prism 6.
ROS and lipid ROS assay. Cellular lipid ROS were measured as 
previously described (9). Briefly, 600,000 cells per well were seeded 
in a 6-well plate. The next day, cells were treated with stimuli and 
harvested. Then cells were resuspended in 500 μl PBS containing 
DHR123 (1 μM) and C11-BODIPY (581/591) (2 μM) and incubated for 
10 minutes at 37°C. Cells were then resuspended in 500 μl of fresh 
PBS containing SytoxBlue (1.25 μM) and analyzed by flow cytometry 
(BD FACSVerse, BD Biosciences).
GSH level measurement. Glutathione levels were measured using 
QuantiChrom Glutathione Assay Kit (BioAssay Systems, DIGT-250). 
Briefly, cells were seeded at 2 × 106 cells in a 5-cm dish. The next day, 
cells were treated with DMSO or WA and erastin. Cells were collected 
and transferred to a new tube, and centrifuged at 425 g at 4°C for 5 
minutes. The cell pellet was resuspended in 300 μM of PBS and was 
lysed by sonication. The lysate was centrifuged at 18,500 g at 4°C for 
10 minutes, and cleared lysate was used to determine the amount of 
GSH in the sample according to the instructions of the kit.
GPX4 assay. Cells were seeded at 6 × 106 cells in 10-cm dishes. The 
next day, cells were treated with WA or DMSO at the indicated time 
points. Cell were washed once with cold PBS and then collected and 
centrifuged at 425 g for 5 minutes. Then the cell pellet was resuspended 
in 200 μl of lysis buffer (KH2PO4/K2HPO4, pH 7.4, containing EDTA 1 
mM, KCl 150 mM, CHAPS 0.1%, β-mercaptoethanol 2 mM, protease 
inhibitor). Lysates were then centrifuged at 20, 800 g for 10 minutes 
at 4°C. One hundred microliters of the lysate was added to 100 μl of 
assay buffer (100 mM KH2PO4/K2HPO4, pH 7.4, containing EDTA 
1 mM, peroxide-free Triton X-100 0.1 %, GSH 4 mM, NADPH 0.4 
mM, and glutathione reductase 4 U/ml) and transferred to a 96-well 
plate. Finally, 10 μl of PCOOH 2.5 μM substrate was added, and the 
amount of NADPH in the reaction mixture was determined kinetically 
by reading of absorbance value at 340 nm at 10-second intervals over 
a period of 10 minutes. GPX activity was normalized to amount of pro-
tein in each sample and reported as percentage considering DMSO 
sample as 100% reference or nanomoles PCOOH reduced per minute 
per milligram of protein. PCOOH was obtained from Marcus Conrad, 
Helmholtz Zentrum München, Institute of Developmental Genetics.
Covalent docking of WA with GPX4. The human phospholipid 
hydroperoxide glutathione peroxidase 4 (GPX4) (PDB: 2OBI) (58) 
Hospital, Medical Research Building, Ghent, Belgium. CHP-212 and 
NB69 cells were obtained from Simone Fulda, Institute for Experi-
mental Cancer Research in Pediatrics, Goethe-University. Other neu-
roblastoma cells were obtained from Paul G. Ekert, Cancer Research, 
Murdoch Children’s Research Institute, Royal Children’s Hospital.
In vivo mouse studies. Briefly, IMR-32 cells were collected and sus-
pended at a density of 8 × 106 in 70 μl PBS and then mixed with 70 
μl of Matrigel matrix. The cell suspension was injected into BALB/c 
nude mice subcutaneously. In the prevention study, the next day 
mice were randomized to 2 groups, and 200 μl of vehicle (PBS 50%, 
DMSO 20%, PEG300 30%) or WA (vehicle containing 4 mg/kg of 
WA) was injected subcutaneously to the same site for 4 consecutive 
days. Tumor size was measured for 2 weeks. In the therapeutic study, 
a setup of an interrupted bisequential or continuous intratumoral WA 
treatment regime was used when the tumor reached an average vol-
ume of either 60 or 100–200 mm3, respectively. In the bisequential 
treatment, 4 consecutive days of WA (4 mg/kg) or vehicle, then 6 days 
of recovery was followed by 3 more daily treatments. In a continuous 
regime, WA (4mg/kg) was injected daily for maximum 20 days. In the 
therapeutic study with WA-NPs, when the tumors reached a volume 
of 60 mm3 on average, mice were injected intraperitoneally and then 
twice peritumorally (days 1 and 5) with WA-NPs or Empty-NPs for a 
period of 2 weeks. To verify effective tumor targeting, mice injected 
intraperitoneally with Cy5-containing nanoparticles or nonencapsu-
lated Cy5 for 3 consecutive days were imaged using the IVIS Spec-
trum In Vivo Imaging System (PerkinElmer). Tumors were measured 
by electronic caliper every day in 3 dimensions (length, width, height) 
with the formula V = 1/2 × W × H × L, where V is the tumor volume, L is 
the length, W is the width, and H is the height. For all local injections 
mice were anesthetized by isoflurane.
Chicken chorioallantoic membrane assay. Chorioallantoic membrane 
(CAM) assay was performed as previously described (56). Briefly, 1 × 
106 SH-EP cells were resuspended in 10 μl NaCl 0.9% and 10 μl Matri-
gel matrix implanted on the CAM of fertilized chicken eggs on day 8 of 
incubation and allowed to form tumor. The next day, tumor was treated 
with WA (2.5 μM) or DMSO daily for 3 days. Four days after inoculation, 
tumors were excised with the surrounding CAM, fixed in 4% parafor-
maldehyde, embedded in paraffin, cut in 5-μm sections, and stained 
with 1:1 hematoxylin and 0.5% eosin solution for histological analysis. 
Images were taken with a 3DHISTECH MIDI Confocal scanner Plan-
Apo ×20/0.8 NA dry objective and a Confocal PCO.edge camera, and 
the tumor area was analyzed using ImageJ software (NIH).
Lentiviral transduction. GPX4 overexpression in IMR-32 cells was 
achieved by lentiviral transduction. Briefly, 1 × 106 HEK293T cells were 
transfected using calcium phosphate with lentiviral expression vector 
p442-PL1 containing murine active GPX4 or inactive GPX4 (Sec/Ser) 
in combination with lentiviral packaging vectors pMD2-VSVG and 
pCMV-DR8.91. The medium was changed after 6 hours, and virus was 
collected 48 hours after transfection. The virus-containing supernatant 
was then used to transduce IMR-32 cells. The GPX4-overexpressing 
cells were then sorted and collected based on expression of GFP flu-
orescence by use of flow cytometry. Lentiviral expression vector p442-
PL1 was obtained from Marcus Conrad, Helmholtz Zentrum München, 
Institute of Developmental Genetics.
Analysis of cell death and caspase-3 activity. Cell death and caspase 
activity were measured as previously described using the FLUOstar 
Omega fluorescence plate reader (BMG Labtech GmbH) (57). Brief-
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responsive nanoparticles by solvent displacement. WA (6 mg) and poly-
mer (180 mg) were dissolved in 15 ml acetone. This solution was prompt-
ly added to 30 ml sterile PBS and mixed. The mixture was sonicated for 
1 hour, acetone was slowly evaporated under reduced pressure, and ster-
ile water was added to compensate for the evaporated volume of water. 
Empty-NPs were made using a similar protocol without addition of WA. 
All used glasswork and material were sterilized before use. Sterile sol-
vents were used or solvent was subjected to sterile filtration before use.
Immunohistochemistry. Tumors were dissected and fixed in 4% 
paraformaldehyde overnight. Subsequently tissue was embedded 
in paraffin and cut in 4- to 5-μm sections. Afterward, sections were 
dewaxed and incubated in antigen retrieval solution (DAKO, s2031) 
at boiling temperature for 10 minutes (for caspase-3, CD45 staining) 
and for 2.5 hours (for Ki67 staining). After being cooled at room tem-
perature, endogenous peroxidase activity was blocked by immersion of 
the slides in peroxidase-blocking buffer (PBS solution containing 0.1% 
hydrogen peroxide, 0.6% sodium azide) for 20 minutes at room tem-
perature. Blocking buffer (10% goat serum, 1% BSA in PBS) was added 
to the slides for 20–30 minutes at room temperature. Primary antibody 
diluted in blocking buffer was incubated at 4°C overnight or at room 
temperature for 1 hour. For caspase-3 staining, slides were incubated 
with secondary antibody for 1 hour, and peroxidase was detected by 
diaminobutyric acid substrate (DAKO, K3468). Slides were counter-
stained with Mayer’s hematoxylin for 20 seconds and were mounted. 
For Ki67 and CD45 staining, slides were incubated with biotinylated 
secondary antibody for 40 minutes. Then, slides were incubated with 
VECTASTAIN ELITE ABC reagent (Vector Laboratories, PK-6100) 
for 20 minutes, and peroxidase was detected by diaminobutyric acid 
substrate. Slides were counterstained with Mayer’s hematoxylin for 20 
seconds and were mounted. Images were captured with an Axio Scan.
Z1 (Zeiss). Images were acquired with a ×20 Plan-Apochromat 0.8 NA 
dry objective using a Hitachi HV-F202SCL camera and processed with 
ZEN 2012 (blue edition, Zeiss) software.
TUNEL assay. TUNEL assay was performed by use of an in situ cell 
death detection kit (TMR-red, Roche). Tumor section slide (as described 
in the Immunohistochemistry section) was dewaxed and incubated with 
permeabilization solution (0.1% Triton X-100 in 0.1% sodium citrate) 
for 8 minutes at room temperature. Then TUNEL reaction mixture was 
added to the slides and incubated on the slides for 1 hour at 37°C. The 
nuclei were counterstained with DAPI (Invitrogen), and the slide was 
mounted and scanned with an Axio Scan.Z1 (Zeiss) using a ×20 Plan- 
Apochromat 0.8 NA dry objective using a Hitachi HV-F202SCL camera. 
Images were processed by ZEN 2012 (blue edition, Zeiss) software.
Live cell imaging. One day before the experiment, cells were seeded 
(30,000 SK-N-SH cells and 50,000 IMR-32 cells per well) in an 8-well 
μ-slide (Ibidi). The next day, the medium was replaced and SytoxGreen 
(10 nM) was added to medium at least 30 minutes before imaging. Cells 
were treated with WA or DMSO, and time series were acquired with an 
LSM780 confocal microscope (Zeiss) using a ×63 Plan-Apochromat 
1.40 NA oil-immersion objective. The pinhole was set at 1 Airy unit (the 
theoretical point for optimal confocal image collection). In another set-
up, time series were acquired with a Zeiss Spinning Disk microscope 
using a ×40 Plan-Apochromat 1.40 NA oil-immersion objective and 
captured with a Rolera electron-multiplying charge-coupled device. 
Images were taken at intervals of 5 minutes for 16 hours while the 
system was maintained at 37°C and 5% CO2. Image reconstruction 
was performed on ImageJ software.
was retrieved from the Protein Data Bank (PDB) (https://www.rcsb.
org) and prepared using the protein preparation wizard implemented 
in Schrödinger’s Maestro suite (version 2015-3, Schrödinger LLC) by 
applying standard default settings and restrained minimization with 
OPLS 2005 force field (59). The small molecules altretamine (CID: 
2123), withaferin A (CID: 265237), and ML162 (CID: 3689413) were 
downloaded from the PubChem database (https://pubchem.ncbi.
nlm.nih.gov) and prepared using ligand preparation implemented in 
Schrödinger’s Maestro (version 2015-3, Schrödinger LLC). Because 
of the good level of accuracy in determining bioactive conformations, 
AutoDock Vina software was applied to perform our primary dock-
ing protocols (60). The search space was included in a box of about 
14 by 12 by 12 Å, with a grid spacing of 1.0 Å and centered on specif-
ic cysteine residues (Cys12, 46, 66, 75, 107, 148) of GPX4, respective-
ly. Scoring function determined by AutoDock Vina revealed that only 
Cys107 residues possess higher consistent binding affinity with all 3 
docked compounds tested. Hence, Cys107 was selected as a starting 
point for subsequent covalent docking. Next, Schrödinger’s Maestro 
suite 2015-3 was selected for performing robust covalent docking. 
The grid for covalent docking was identified with SiteFinder imple-
mented in MOE (version 2015.1001; Chemical Computing Group; 
https://www.chemcomp.com/MOE-Molecular_Operating_Environ-
ment.htm). The grid box is defined as a spherical region encompass-
ing Gln77, Ile106, Asp111, and His114 residues including Cys107 as 
reactive residue. Moreover, we predefined reaction type for each com-
pound before proceeding with covalent docking: Michael addition and 
nucleophilic addition for WA, alkylation for altretamine, and nucle-
ophilic addition for ML162. To properly validate the covalent docking 
protocol, we changed grid to verify stringency of docking and scoring 
function. In addition, post-processing after covalent docking was per-
formed by molecular mechanics energies combined with the Poisson- 
Boltzmann or generalized Born and surface area continuum solvation 
(MM/PBSA and MM/GBSA) (61). Three-dimensional molecular inter-
actions of the docked ligands in GPX4 are displayed by PyMOL; arbitrary 
distances from ligand reactive groups to the specific cysteines were cal-
culated using the measurement wizard in PyMOL (PyMOL Molecular 
Graphics System version 1, Schrödinger LLC).
mRNA bead array and data processing. Total RNA from control and 
WA-treated (1 μM, 24 hours) IMR-32 and SK-N-SH cells was isolated 
using RNeasy Mini Kit (Qiagen, 74104) according to the manufacturer’s 
protocol. After checking of quality control of RNA on a Bio-Rad Experion 
electrophoresis system, 500 ng of total RNA was amplified using the Illu-
mina TotalPrep RNA Amplification kit (Life Technologies). Briefly, RNA 
was reverse-transcribed using T7 oligo-dT primers, after which bioti-
nylated cRNA was synthesized through an in vitro transcription reaction. 
Seven hundred fifty nanograms of amplified cRNA was hybridized to a 
corresponding array of a HumanHT12 beadchip (Illumina), essentially as 
previously described (15). Transcriptomic analysis was done by uploading 
Illumina bead array gene expression data into IPA (QIAGEN Inc., https://
www.qiagenbioinformatics.com/products/ingenuitypathway-analysis) 
and performing a core analysis. A fold change cutoff of 2 as well as an 
FDR of 5% was set to identify genes whose expression was significantly 
differentially regulated. A heatmap was created from the genes related to 
oxidative pathways using the heatmap.2 function of the gplots R package. 
Raw and normalized array data were uploaded to the Gene Expression 
Omnibus (GEO) database with accession number GSE112384.
Synthesis of WA-NP. WA was formulated in biodegradable pH- 
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Immunoprecipitation of biotinylated WA. IMR-32 cells were seeded 
at 6 × 106 in a 10-cm dish. The next day, cells were treated with the 
triggers (WA, biotin, biotin-WA) for 1 hour. Then cells were washed 
with PBS and lysed in NP-40 lysis buffer (NaCl 150 mM, NP-40 1%, 
glycerol 10%, Tris-HCl, pH 8, 10 mM) supplemented with EDTA-free 
protease inhibitor cocktail tablets (Roche Diagnostics, 11873580001) 
and phosphatase inhibitor cocktail tablets (Roche Diagnostics, 
04906837001). Lysate was collected and transferred to vials and 
rotated at 4°C for 15 minutes. Afterward, the lysate was centrifuged 
at the highest speed at 4°C for 15 minutes. Supernatant was collected, 
added to streptavidin-Sepharose beads, and incubated at 4°C over-
night. The next day, beads were washed 3 times in NP-40 lysis buffer, 
and the immunoprecipitated proteins were eluted by addition of 60 μl 
of ×2 Laemmli buffer to the beads. Eluted proteins were subsequently 
analyzed by immunoblotting.
Determination of cellular labile Fe(II) pool. Iron measurement was 
performed using FeRhoNox-1. Briefly, 1 × 106 IMR-32 cells were seeded 
in a 6-well plate 1 day before the experiment. The next day, cells were 
collected and centrifuged at 3,000 g for 5 minutes. The cells were 
washed with HBSS buffer and centrifuged at 3,000 g for 5 minutes. 
Collected cells were stained with 10 μM FeRhoNox-1 in HBSS for 30 
minutes in a CO2 incubator. Then cells were washed with HBSS and 
dissolved in 300 μl of HBSS containing 1.25 μM SytoxBlue and were 
analyzed using flow cytometry.
LC-MS analysis of phospholipids. Phospholipids from tumor 
tissue were analyzed by liquid chromatography–mass spectrometry 
(LC-MS) as previously described (62). Briefly, lipids were sepa-
rated on a normal phase column [Luna 3 μm Silica(2) 100Å, 150 × 
2.0 mm, Phenomenex] at a flow rate of 0.2 ml/min using a Dionex 
Ultimate 3000 HPLC system. The column was maintained at 35°C. 
The analysis was performed with gradient solvents (A: propanol/
hexane/water, 285:215:5 vol/vol/vol; B: propanol/hexane/water, 
285:215:40 vol/vol/vol) containing 10 mM ammonium acetate and 
0.5% triethylamine. The column was eluted for 0.5 minutes isocra-
tically at 25% solvent B; then from 0.5 to 6.5 minutes with a linear 
gradient of 25% to 40% solvent B, from 6.5 to 25 minutes with a 
linear gradient of 40% to 55% solvent B, from 25 to 38 minutes with 
a linear gradient of 55% to 70% solvent B, and from 38 to 48 minutes 
with a linear gradient of 70% to 100% solvent B; then isocratically 
from 48 to 55 minutes at 100% solvent B followed by a return to ini-
tial conditions from 55 to 70 minutes from 100% to 25% solvent B. 
The column was then equilibrated at 25% solvent B for an additional 
5 minutes. All solvents were LC-MS grade.
Statistics. Tumor size data (mm3) were analyzed as repeated 
measurements, modeling the correlation structure and using the 
residual maximum likelihood (REML) as implemented in GenStat 
version 17 (https://genstat.kb.vsni.co.uk/). Significance of the main 
and interaction effects was assessed by an F test. Cell death data 
were analyzed as previously described (57). Briefly, cell death data 
were analyzed as repeated measurements, modeling the correlation 
structure and using the REML as implemented in GenStat version 
17. Significance of the main and interaction effects was assessed by 
an F test. Other statistical analysis was performed using GraphPad 
Prism 7 software. P values less than 0.05 were considered significant.
Study approval. The present studies in animals were reviewed and 
approved by the Ethics Committee for Laboratory Animal Experi-
ments of Ghent University, Faculty of Sciences, Ghent, Belgium.
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